Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Partnered Content
Meet the Team
Ask the Analyst
RSS Feeds
Subscribe
Advertise
Contact Us
FAQs
Reports Store
UsernamePublicRestriction
Tags:
Value-Added Medicines Launches United States

Sandoz Phases US Epinephrine Entry

  • News

Executive Summary

Sandoz will first focus on the US institutional channel on which it is increasingly concentrating its attention as it rolls out its alternative to Mylan’s EpiPen epinephrine auto-injector.
Table

View full table

Advertisement

Related Content

Generics Bulletin
Sandoz Chalks Up A Third US Launch of 2019 With The First Generic Suprane
Generics Bulletin
Sandoz Will Differentiate To Serve A Different World
Generics Bulletin
Sandoz’ Symjepi Set To Undercut Rivals
Generics Bulletin
Teva bags first EpiPen approval
Generics Bulletin
Sandoz bags US epinephrine

Topics

What to read next

Advertisement
Tags:
Value-Added Medicines Launches United States
UsernamePublicRestriction

Register

GB139999

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By